von Eyben, R.; Hoffmann, M.A.; Soydal, C.; Virgolini, I.; Tuncel, M.; Gauthé, M.; Kapp, D.S.; von Eyben, F.E.
Pretest PSA and Restaging PSMA PET/CT Predict Survival in Biochemically Recurrent Prostate Cancer. Biomedicines 2023, 11, 2333.
https://doi.org/10.3390/biomedicines11092333
AMA Style
von Eyben R, Hoffmann MA, Soydal C, Virgolini I, Tuncel M, Gauthé M, Kapp DS, von Eyben FE.
Pretest PSA and Restaging PSMA PET/CT Predict Survival in Biochemically Recurrent Prostate Cancer. Biomedicines. 2023; 11(9):2333.
https://doi.org/10.3390/biomedicines11092333
Chicago/Turabian Style
von Eyben, Rie, Manuela Andrea Hoffmann, Cigdem Soydal, Irene Virgolini, Murat Tuncel, Mathieu Gauthé, Daniel S. Kapp, and Finn Edler von Eyben.
2023. "Pretest PSA and Restaging PSMA PET/CT Predict Survival in Biochemically Recurrent Prostate Cancer" Biomedicines 11, no. 9: 2333.
https://doi.org/10.3390/biomedicines11092333
APA Style
von Eyben, R., Hoffmann, M. A., Soydal, C., Virgolini, I., Tuncel, M., Gauthé, M., Kapp, D. S., & von Eyben, F. E.
(2023). Pretest PSA and Restaging PSMA PET/CT Predict Survival in Biochemically Recurrent Prostate Cancer. Biomedicines, 11(9), 2333.
https://doi.org/10.3390/biomedicines11092333
